111 related articles for article (PubMed ID: 15828551)
1. Clinical trials referral resource. Current clinical trials investigating 3-AP.
Low JA; Schoenfeldt M
Oncology (Williston Park); 2005 Mar; 19(3):354, 357-8. PubMed ID: 15828551
[No Abstract] [Full Text] [Related]
2. A new era for ribonucleoside reductase inhibition.
Giles FJ
Leuk Res; 2007 Sep; 31(9):1163-4. PubMed ID: 17416414
[No Abstract] [Full Text] [Related]
3. Alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone inhibitors of ribonucleoside diphosphate reductase.
Booth BA; Agrawal KC; Moore EC; Sartorelli AC
Cancer Res; 1974 Jun; 34(6):1308-14. PubMed ID: 4363653
[No Abstract] [Full Text] [Related]
4. Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Tsimberidou AM; Alvarado Y; Giles FJ
Expert Rev Anticancer Ther; 2002 Aug; 2(4):437-48. PubMed ID: 12647987
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Zeidner JF; Karp JE; Blackford AL; Smith BD; Gojo I; Gore SD; Levis MJ; Carraway HE; Greer JM; Ivy SP; Pratz KW; McDevitt MA
Haematologica; 2014 Apr; 99(4):672-8. PubMed ID: 24362550
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Barker CA; Burgan WE; Carter DJ; Cerna D; Gius D; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2006 May; 12(9):2912-8. PubMed ID: 16675588
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Gojo I; Tidwell ML; Greer J; Takebe N; Seiter K; Pochron MF; Johnson B; Sznol M; Karp JE
Leuk Res; 2007 Sep; 31(9):1165-73. PubMed ID: 17324462
[TBL] [Abstract][Full Text] [Related]
8. Ribonucleotide reductase inhibitors as anti-herpes agents.
Wnuk SF; Robins MJ
Antiviral Res; 2006 Sep; 71(2-3):122-6. PubMed ID: 16621038
[TBL] [Abstract][Full Text] [Related]
9. Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors.
Yu Y; Kalinowski DS; Kovacevic Z; Siafakas AR; Jansson PJ; Stefani C; Lovejoy DB; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2009 Sep; 52(17):5271-94. PubMed ID: 19601577
[No Abstract] [Full Text] [Related]
10. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs.
Li J; Zheng LM; King I; Doyle TW; Chen SH
Curr Med Chem; 2001 Feb; 8(2):121-33. PubMed ID: 11172670
[TBL] [Abstract][Full Text] [Related]
11. Developmental clinical trials: building one step at a time.
Karp JE; Smith BD
Leuk Res; 2006 Jul; 30(7):765-6. PubMed ID: 16490252
[No Abstract] [Full Text] [Related]
12. Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates.
Kunos CA; Colussi VC; Pink J; Radivoyevitch T; Oleinick NL
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1198-204. PubMed ID: 21470790
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials referral resource. Current clinical trials investigating Triapine.
Schoenfeldt M
Oncology (Williston Park); 2004 Aug; 18(9):1147, 1149-50. PubMed ID: 15471198
[No Abstract] [Full Text] [Related]
14. Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.
Wright JJ; Zerivitz K; Gravell A
Oncology (Williston Park); 2005 Apr; 19(4):499-502. PubMed ID: 15934518
[No Abstract] [Full Text] [Related]
15. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
16. Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
Kunos C; Radivoyevitch T; Abdul-Karim FW; Fanning J; Abulafia O; Bonebrake AJ; Usha L
J Transl Med; 2012 Apr; 10():79. PubMed ID: 22541066
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.
Kunos CA; Radivoyevitch T; Pink J; Chiu SM; Stefan T; Jacobberger J; Kinsella TJ
Radiat Res; 2010 Nov; 174(5):574-81. PubMed ID: 20954859
[TBL] [Abstract][Full Text] [Related]
18. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.
Finch RA; Liu MC; Cory AH; Cory JG; Sartorelli AC
Adv Enzyme Regul; 1999; 39():3-12. PubMed ID: 10470363
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase.
Zhu L; Zhou B; Chen X; Jiang H; Shao J; Yen Y
Biochem Pharmacol; 2009 Nov; 78(9):1178-85. PubMed ID: 19576866
[TBL] [Abstract][Full Text] [Related]
20. Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.
Kunos CA; Chiu SM; Pink J; Kinsella TJ
Radiat Res; 2009 Dec; 172(6):666-76. PubMed ID: 19929413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
